Natera (NASDAQ:NTRA) Given New $165.00 Price Target at Canaccord Genuity Group

Natera (NASDAQ:NTRA - Get Free Report) had its target price upped by equities research analysts at Canaccord Genuity Group from $150.00 to $165.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the medical research company's stock. Canaccord Genuity Group's price target indicates a potential upside of 2.50% from the stock's current price.

A number of other equities analysts also recently commented on the stock. Piper Sandler reiterated an "overweight" rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. Sanford C. Bernstein increased their target price on shares of Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Morgan Stanley increased their target price on shares of Natera from $125.00 to $132.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 13th. TD Cowen increased their target price on shares of Natera from $137.00 to $145.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Finally, The Goldman Sachs Group increased their target price on shares of Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $135.06.

Natera Trading Up 19.1 %

NASDAQ NTRA traded up $25.85 during trading hours on Wednesday, hitting $160.97. 4,521,602 shares of the company were exchanged, compared to its average volume of 1,328,347. The stock has a 50-day moving average price of $125.09 and a 200 day moving average price of $114.52. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. Natera has a 52 week low of $49.97 and a 52 week high of $167.69. The stock has a market cap of $19.91 billion, a PE ratio of -94.03 and a beta of 1.53.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.88% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts' expectations of $361.43 million. During the same quarter in the prior year, the firm posted ($0.95) earnings per share. The company's quarterly revenue was up 63.9% on a year-over-year basis. Analysts forecast that Natera will post -1.96 earnings per share for the current fiscal year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 4,523 shares of Natera stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the sale, the chief executive officer now owns 191,163 shares of the company's stock, valued at $24,927,655.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Steven Leonard Chapman sold 4,523 shares of the business's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total value of $589,799.20. Following the completion of the sale, the chief executive officer now owns 191,163 shares of the company's stock, valued at approximately $24,927,655.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Solomon Moshkevich sold 256 shares of the business's stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the sale, the insider now directly owns 111,891 shares of the company's stock, valued at $13,434,752.37. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,464 shares of company stock worth $5,849,977. 7.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Brooklyn Investment Group bought a new position in shares of Natera in the third quarter worth about $70,000. Millrace Asset Group Inc. grew its position in shares of Natera by 22.5% during the 3rd quarter. Millrace Asset Group Inc. now owns 12,144 shares of the medical research company's stock worth $1,542,000 after buying an additional 2,228 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Natera by 87.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company's stock worth $8,621,000 after buying an additional 31,649 shares during the period. Harvest Fund Management Co. Ltd grew its position in shares of Natera by 90.7% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 7,774 shares of the medical research company's stock worth $987,000 after buying an additional 3,697 shares during the period. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Natera during the 3rd quarter worth approximately $232,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.